Chronic Pain Protocol
| Category | Protocols |
|---|---|
| Also known as | Pain Management Peptide Protocol, BPC-157 Pain Protocol, Cerebrolysin Pain Stack |
| Last updated | 2026-04-14 |
| Reading time | 7 min read |
| Tags | protocolspainchronic-painbpc-157cerebrolysinneuropathic |
Overview
Chronic pain — defined as pain persisting beyond normal tissue healing time (typically 3–6 months) — affects an estimated 20–30% of adults worldwide and represents a distinct pathological state rather than simply prolonged acute pain. Chronic pain involves neuroplastic changes in the nervous system, including peripheral sensitization, central sensitization (spinal cord wind-up), altered brain processing, and neuroinflammation. These changes mean the pain system itself becomes dysfunctional, often generating pain signals that no longer correlate with tissue damage.
Conventional chronic pain management has relied heavily on NSAIDs (which carry gastrointestinal and cardiovascular risks with long-term use), opioids (with well-documented risks of dependence, tolerance, and hyperalgesia), and adjuvant medications (gabapentinoids, SNRIs, tricyclic antidepressants). Peptide-based approaches offer a different angle, targeting tissue repair (BPC-157) and neurotrophic support (Cerebrolysin) rather than simply blocking pain signals.
This protocol is not a replacement for comprehensive pain management. It is positioned as an adjunct to physical rehabilitation, psychological approaches, and appropriate medical treatment.
Compounds Involved
| Compound | Class | Primary Effects | Route | Typical Dose |
|---|---|---|---|---|
| BPC-157 | Gastric pentadecapeptide | Tissue repair, angiogenesis, anti-inflammatory | SubQ (local or systemic) | 250–500 mcg 2x/day |
| Cerebrolysin | Neurotrophic peptide mixture | Neurotrophic support, neuroprotection, neuroregeneration | IM or IV | 5–10 mL/day (course-based) |
| PEA (Palmitoylethanolamide) | Endocannabinoid-like lipid | Mast cell regulation, glial modulation, anti-inflammatory | Oral | 600–1,200 mg/day |
| LDN (Low-Dose Naltrexone) | Opioid antagonist (microglial modulator) | Glial cell modulation, endorphin upregulation | Oral | 1.5–4.5 mg/day |
BPC-157
BPC-157 is relevant to chronic pain protocols through multiple mechanisms. Where pain is maintained by ongoing tissue pathology (tendinopathy, joint degeneration, post-surgical adhesions), BPC-157's tissue-healing properties may address the structural source. Additionally, BPC-157 has demonstrated effects on nitric oxide modulation, dopaminergic system interaction, and reduction of inflammation — all relevant to pain processing.
Local injection near the pain source is the most common approach for musculoskeletal pain, while systemic injection or oral administration (see Gut Permeability Protocol) may be preferred for diffuse or centralized pain conditions.
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue. It contains active fragments of various neurotrophic factors including BDNF, GDNF, NGF, and CNTF-like activities. Originally developed for stroke recovery and neurodegenerative conditions, Cerebrolysin has research relevance to chronic pain through its neurotrophic and neuroregenerative properties — particularly for neuropathic pain where nerve damage or dysfunction drives the pain state.
Cerebrolysin is typically administered intramuscularly or intravenously in course-based protocols (daily treatment for 10–20 days, followed by a break period). It requires medical supervision for administration.
Supportive Compounds
PEA (Palmitoylethanolamide): An endogenous fatty acid amide that modulates mast cells and glial cells — both key players in chronic pain maintenance. PEA is available as a supplement and has clinical trial evidence supporting its use in neuropathic and chronic inflammatory pain conditions.
LDN (Low-Dose Naltrexone): At low doses (1.5–4.5 mg), naltrexone acts as a glial cell modulator rather than an opioid antagonist, reducing neuroinflammation and upregulating endogenous opioid production. LDN requires a prescription and compounding pharmacy.
Protocol Structure
Phase 1: Assessment and Foundation (Weeks 1–4)
Pain characterization: Identify the dominant pain mechanism, as this directs the protocol emphasis:
| Pain Type | Characteristics | Primary Peptide Focus |
|---|---|---|
| Nociceptive (structural) | Localized, correlates with movement/loading, identifiable tissue source | BPC-157 local injection |
| Neuropathic | Burning, shooting, electric, numbness/tingling, dermatomal pattern | Cerebrolysin + PEA |
| Central sensitization | Widespread, disproportionate to stimulus, allodynia, hyperalgesia | PEA + LDN + Cerebrolysin |
| Mixed | Combination of the above | Multi-target approach |
Foundation protocol:
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| PEA (micronized) | 600 mg | 2x daily | Build up over 2 weeks |
| Omega-3 (EPA-dominant) | 3–4 g | Daily with meals | Anti-inflammatory |
| Magnesium glycinate | 400 mg | Evening | Muscle relaxation, NMDA modulation |
| Vitamin D3 | 5,000 IU | Morning | Deficiency worsens pain sensitivity |
Phase 2: Peptide Introduction (Weeks 5–14)
For nociceptive/structural pain:
| Compound | Dose | Frequency | Route |
|---|---|---|---|
| BPC-157 | 250–500 mcg | 2x daily | SubQ near pain source |
| TB-500 | 2–5 mg | 2x weekly | SubQ systemic (optional) |
| PEA | 600 mg | 2x daily | Oral |
For neuropathic pain:
| Compound | Dose | Frequency | Route |
|---|---|---|---|
| Cerebrolysin | 5–10 mL | Daily for 10–20 days | IM (medical supervision) |
| PEA | 600 mg | 2x daily | Oral |
| LDN | 1.5 mg, titrate to 4.5 mg | Daily at bedtime | Oral (prescription) |
For central sensitization:
| Compound | Dose | Frequency | Route |
|---|---|---|---|
| LDN | 1.5–4.5 mg (titrated) | Daily at bedtime | Oral (prescription) |
| PEA | 600 mg | 2x daily | Oral |
| Cerebrolysin | 5 mL | Daily for 10 days | IM (medical supervision) |
| BPC-157 | 250 mcg | 2x daily | SubQ or oral |
Phase 3: Rehabilitation Integration (Weeks 6+)
Peptide protocols for chronic pain are most effective when combined with active rehabilitation approaches:
- Graded exercise therapy: Progressive, pain-science-informed exercise beginning below pain threshold and gradually increasing
- Pain neuroscience education: Understanding that chronic pain reflects nervous system sensitization rather than ongoing tissue damage can itself reduce pain intensity
- Manual therapy: Mobilization, myofascial release, and other hands-on techniques as adjuncts
- Mind-body practices: Meditation, yoga, tai chi — all have evidence supporting chronic pain management
- Sleep optimization: Pain disrupts sleep, and sleep disruption amplifies pain. See Sleep Optimization Protocol
Cerebrolysin Course Protocol
Cerebrolysin is administered in defined courses rather than continuously:
Standard course:
- 5–10 mL daily via intramuscular injection for 10–20 consecutive days
- Rest period of 4–8 weeks
- Repeat course as needed (typically 2–4 courses per year)
Important notes:
- Cerebrolysin requires medical supervision for administration
- IM injection into large muscle groups (gluteal, deltoid)
- IV administration (diluted in saline over 15–60 minutes) is used in clinical settings
- Do not mix with balanced amino acid infusion solutions
Important Considerations
- Multimodal approach: Chronic pain rarely responds to any single intervention. This protocol is one component of a comprehensive pain management strategy.
- Opioid considerations: If currently using opioid medications, LDN is contraindicated (it blocks opioid receptors). LDN requires complete opioid washout before initiation. Discuss with your prescribing physician.
- Patience: Chronic pain neuroplasticity develops over months to years. Reversal also takes time. Expect gradual improvement over weeks to months rather than dramatic overnight changes.
- Flare management: Pain flares are normal during recovery. Having a flare plan (rest, modified activity, ice/heat, breathing techniques) prevents catastrophizing and setbacks.
- Nerve recovery context: For specific nerve injury or compression, see the Nerve Recovery Protocol for targeted approaches.
- Quality: Source all peptides from reputable vendors. See Purity and Testing.
Disclaimer
This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.
Related entries
- BPC-157— A 15-amino-acid peptide derived from human gastric juice protein BPC, extensively studied in animal models for its role in tissue repair, cytoprotection, and wound healing acceleration.
- Cerebrolysin— A porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids, approved in over 40 countries for stroke, traumatic brain injury, and dementia, though not FDA-approved in the United States.
- Joint Support Protocol— A protocol targeting joint health and connective tissue repair using BPC-157, TB-500, and Pentosan Polysulfate, with specific guidance for tendon, ligament, and cartilage support.
- Nerve Recovery Protocol— A structured protocol combining BPC-157, Cerebrolysin, and Semax for peripheral and central nerve recovery, covering neuroprotective and neuroregenerative peptide strategies.
- Tendon and Ligament Repair Protocol— A targeted peptide protocol for supporting tendon and ligament repair, addressing the unique challenges of connective tissue healing including poor blood supply, slow collagen turnover, and the risk of incomplete remodeling.